menu
    • menu

    Company profile for Dyne Therapeutics

    NEW Drugs in Dev: 4
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dyne TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Technology Square 10th Floor Cambridge, MA, 02139
    Telephone
    Telephone
    (508) 277-8117
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dyne-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dynetx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/dyne_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dyne Therapeutics' DYNE-101 Gets Orphan Status in Japan for DM1
    Dyne Therapeutics' DYNE-101 Gets Orphan Status in Japan for DM1

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221596/0/en/Dyne-Therapeutics-Receives-Orphan-Drug-Designation-in-Japan-for-Zeleciment-Basivarsen-DYNE-101-for-Myotonic-Dystrophy-Type-1.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Dyne Therapeutics To Present At J.P. Morgan Healthcare Conference
    Dyne Therapeutics To Present At J.P. Morgan Healthcare Conference

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214423/0/en/Dyne-Therapeutics-to-Present-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors
    Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209804/0/en/Dyne-Therapeutics-Appoints-Vikram-Karnani-to-Board-of-Directors.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Dyne Closes Upsized Offering; Underwriters Exercise Full Option
    Dyne Closes Upsized Offering; Underwriters Exercise Full Option

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204300/0/en/Dyne-Therapeutics-Announces-Closing-of-Upsized-Public-Offering-of-Common-Stock-and-Full-Exercise-by-Underwriters-of-Option-to-Purchase-Additional-Shares.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Dyne readies FDA push after DMD exon 51 med excels in trial
    Dyne readies FDA push after DMD exon 51 med excels in trial

    08 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial

    FIERCE BIOTECH
    08 Dec 2025
    Share Share
    Dyne Therapeutics Plans Public Stock Offering
    Dyne Therapeutics Plans Public Stock Offering

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201961/0/en/Dyne-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search